Heart, Lung and Circulation最新文献

{"title":"Reconsidering First-Line Sternotomy Closure Methodology: Wire Cerclage Versus Rigid Plate Fixation","authors":"Alistair Royse AM, MBBS, MD, FRACS, FCSANZ , Colin Royse MBBS, MD , Doa El-Ansary BAppSc(Phty), Int Cert OMT, PhD, MACP","doi":"10.1016/j.hlc.2025.07.002","DOIUrl":"10.1016/j.hlc.2025.07.002","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 8","pages":"Page 752"},"PeriodicalIF":2.2,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing and Mode of Death Following ECPR: A Single Centre, Retrospective Analysis.","authors":"Humphrey G M Walker, Alexander S Richardson, Arne Diehl, Aidan Burrell","doi":"10.1016/j.hlc.2025.04.072","DOIUrl":"https://doi.org/10.1016/j.hlc.2025.04.072","url":null,"abstract":"<p><strong>Background: </strong>Currently little is known about the timing and modality in which people die following extracorporeal cardiopulmonary resuscitation (ECPR). This is important as it may define potential therapeutic targets, pathways for improvement in ECPR outcomes, and resource implications. Therefore, we undertook a study to analyse the mechanisms and timeframes of death within the first 28 days in a high-volume Australian ECPR centre.</p><p><strong>Method: </strong>This was a single-centre, retrospective review from 1 January 2017 until 31 December 2022. All patients undergoing ECPR were analysed. Modality of death was classified into neurological (subclassified as brain death or withdrawal of life-sustaining treatment [WLST] without brain death) or non-neurological (subclassified as refractory shock or non-neurological WLST).</p><p><strong>Results: </strong>A total of 95 patients were included. Overall, 52/95 (54.7%) had an out-of-hospital cardiac arrest. In total, 51/95 (53.7 %) had died by day 28. The most common modality of death was neurological WLST without brain death. The earliest modality of death to occur was refractory shock. Median survival times were 0 days (interquartile range [IQR] 0-2) for patients with refractory shock, 2 days (IQR 1-4) for brain death, 3 days (IQR 1-8) for non-neurological WLST and 9 days (IQR 2-14) for neurological WLST without brain death. Four (7.8%) patients underwent organ donation.</p><p><strong>Conclusions: </strong>Mortality post ECPR remains high. Refractory shock is the earliest modality of death while neurological WLST without brain death is most common, occurring several days later. Understanding the different phenotypes of death post-ECPR is important to identify future potential therapeutic targets.</p>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective, Multicentre Randomised Controlled Study of Angiographic and Clinical Outcomes in Total Arterial Coronary Bypass Grafting: The TA Trial Protocol.","authors":"Alistair Royse, Justin Ren, Andrea Bowyer, Christopher M Reid, Rinaldo Bellomo, Julian A Smith, Paul Bannon, David Eccleston, Michael Vallely, Elaine Lui, Guy Ludbrook, Sandy Clarke, David H Tian, Colin Royse","doi":"10.1016/j.hlc.2025.06.1018","DOIUrl":"https://doi.org/10.1016/j.hlc.2025.06.1018","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background & aim: &lt;/strong&gt;Conventional coronary artery bypass grafting (CABG) procedures typically utilise the left internal mammary artery and supplementary saphenous vein grafts (SVGs) to re-establish adequate coronary blood flow to ischaemic territories. However, extensive observational studies have consistently demonstrated that SVGs are prone to accelerated atherosclerosis and progressive failure compared to arterial conduits. These limitations have heightened interest in total arterial revascularisation (TAR) as a potentially superior strategy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The Total Arterial (TA) Trial, fully funded through the Medical Research Future Fund Cardiovascular Health Mission, aims to determine the angiographic and clinical outcomes of TAR compared to conventional non-TAR operations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Method: &lt;/strong&gt;Design: This study is an open-label, multicentre, randomised controlled trial including 1,000 CABG patients from multiple cardiac institutions across Australia, with an allocation ratio of 1:1. Randomisation occurs at a standardised perioperative time point via computer-generated sequences with variable block size The trial does not impose specific procedural requirements regarding the type of arterial conduit, revascularisation or reconstruction technique, use of sequential or composite methods, or any perioperative management.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention: &lt;/strong&gt;Total arterial CABG with no use of SVG.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Control: &lt;/strong&gt;Non-total-arterial CABG with at least one SVG.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes: &lt;/strong&gt;The primary endpoint will be perfect graft patency at 24 months postoperatively. The secondary endpoints include patency, major adverse cardiac and cerebrovascular events, quality of life, all-cause and cardiac mortality. Clinical follow-up visits will be scheduled at 6-month intervals, and angiographic assessments at 3 months and 24 months. Subgroup analyses by diabetes, sex, age, and conduit types are proposed to examine the potential interactions with treatment effects.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The TA Trial is one of the largest multicentre trials in the field of coronary revascularisation research, evaluating the graft status and clinical endpoints of TAR versus non-TAR procedures. The study design will provide valuable insights into whether differences in graft failure of SVG translate into differences in survival and cardiac outcomes. Early postoperative coronary angiography may improve understanding of the impact of competitive flow on graft function. The findings from this study will contribute to an improved understanding and help inform the optimal approach for coronary revascularisation, supporting evidence-based improvements in patient care.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Ethics: &lt;/strong&gt;Ethical approval has been granted by the Melbourne Health Institutional Review Board (HREC/92839/MH-2023), Australia.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/strong&gt;The trial has been registered under t","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Riding the Impella Wave in Cardiogenic Shock: Is it Time for Australia to Get on Board?","authors":"Dion Stub MBBS, PhD, FRACP ,&nbsp;Riley J. Batchelor MBBS, MMed, FRACP ,&nbsp;Jason E. Bloom MBBS, FRACP ,&nbsp;David M. Kaye MBBS, PhD, FRACP","doi":"10.1016/j.hlc.2025.06.003","DOIUrl":"10.1016/j.hlc.2025.06.003","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 7","pages":"Pages 662-664"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paid MBP advert: Cardiac Society of Australia and New Zealand","authors":"","doi":"10.1016/S1443-9506(25)00489-5","DOIUrl":"10.1016/S1443-9506(25)00489-5","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 7","pages":"Page 746"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144632101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Expert Opinion on the Management of Frailty in Heart Failure from the Australian Cardiovascular Alliance National Taskforce","authors":"Julee McDonagh MN, PhD ,&nbsp;Caleb Ferguson BN, PhD ,&nbsp;Sarah N. Hilmer PhD ,&nbsp;Ruth E. Hubbard PhD ,&nbsp;Richard I. Lindley MBBS, MD ,&nbsp;Andrea Driscoll BN, PhD ,&nbsp;Andrew Maiorana PhD ,&nbsp;Lindsay Wu PhD ,&nbsp;John J. Atherton PhD ,&nbsp;Beata V. Bajorek PhD ,&nbsp;Bridie Carr BN ,&nbsp;Kim Delbaere PhD ,&nbsp;Elsa Dent PhD ,&nbsp;Mai H. Duong PhD ,&nbsp;Louise D. Hickman BN, PhD ,&nbsp;Ingrid Hopper PhD ,&nbsp;Quan Huynh PhD ,&nbsp;Sunita R. Jha PhD ,&nbsp;Anthony Keech PhD ,&nbsp;Marc Sim PhD ,&nbsp;Peter S. Macdonald MD, PhD","doi":"10.1016/j.hlc.2025.01.012","DOIUrl":"10.1016/j.hlc.2025.01.012","url":null,"abstract":"<div><div>Approximately 50% of all adults with heart failure (HF) are classified as frail. Frailty is a clinical state of 'accelerated ageing' that complicates management and results in adverse health outcomes. Despite recommendations for frailty assessment in HF guidelines, its implementation into routine clinical practice has been slow. Further, evidence to inform models of care and pharmacological treatment for individuals with HF who are classified as frail is lacking. The complexity of management underscores the importance of tailoring models of care that can improve the focus on frailty through multidisciplinary care teams. Frailty can be reduced in some cases through the comprehensive geriatric assessment model of care, integrating treatment pillars such as exercise, nutrition, social engagement and support networks, and optimised medication use. A national agenda for action on frailty in the context of HF is needed to advance policy, practice, education, and research improve health outcomes for individuals affected.</div><div>In November 2023 the Australian Cardiovascular Alliance (ACvA) facilitated a national workshop on frailty and HF with key experts. This has led to the development of a frailty and HF national taskforce with the aim to address major priorities and unmet needs. This statement is first step for the taskforce in implementing a national agenda for the management of frailty in HF. Here we outline key considerations for policy, practice, education, and research in Australia.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 7","pages":"Pages 693-703"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPATA2/CYLD Pathway-Dependent Deubiquitylation of p53 Promotes Ferroptosis in Rat Heart After Ischaemia/Reperfusion Through Suppression of SLC7A11","authors":"Dan-Qing Duan MS ,&nbsp;Ming-Rui Li PhD ,&nbsp;Li-Qun Lu PhD ,&nbsp;Bi-Feng Yao MS ,&nbsp;Lin-Lu Huang BS ,&nbsp;Xiu-Ju Luo PhD ,&nbsp;Jun Peng MD, PhD","doi":"10.1016/j.hlc.2024.11.028","DOIUrl":"10.1016/j.hlc.2024.11.028","url":null,"abstract":"<div><h3>Background &amp; Aim</h3><div>Ferroptosis is an iron-dependent cell death and contributes to myocardial ischaemia/reperfusion (I/R) injury. Downregulation of glutathione peroxidase 4 (GPX4) is a key factor to accelerate ferroptosis, but the underlying mechanisms are not fully elucidated. Solute carrier family 7A member 11 (SLC7A11) plays a key role in maintaining the normal level of GPX4, and its transcription is suppressed by p53, whose level is controlled by spermatogenesis-associated protein 2 (SPATA2)/cylindromatosis (CYLD) pathway in a de-ubiquitination-dependent way. This study aims to explore whether SPATA2/CYLD pathway promotes myocardial ferroptosis in rat hearts after I/R through p53-dependent inhibition of SLC7A11.</div></div><div><h3>Methods</h3><div>The rat hearts were subjected to 1 h-ischaemia plus 3 h-reperfusion to establish a myocardial I/R injury model, and H9c2 cells were subjected to 8 h-hypoxia plus 12 h-re-oxygenation (H/R) to mimic myocardial I/R injury in vitro.</div></div><div><h3>Results</h3><div>Both the rat hearts and the cultured cardiomyocytes showed elevated levels of SPATA2 and CYLD, concomitant with the increased p53 levels and the enhanced interaction between SPATA2 and CYLD; these phenomena were reversed by knockdown of SPATA2. Mechanistically, knockdown of SPATA2 restored the ubiquitination of p53 and decreased p53 level in the H/R-treated cardiomyocytes, accompanied by increases in the levels of SLC7A11 and GPX4, and reduction of ferroptosis. Furthermore, suppression of SPATA2 by lurasidone, a predicted inhibitor of SPATA2, in the I/R-treated rat hearts also achieved similar results.</div></div><div><h3>Conclusion</h3><div>SPATA2/CYLD pathway-dependent de-ubiquitylation of p53 promotes ferroptosis in rat heart after I/R through a mechanism involving suppression of SLC7A11.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 7","pages":"Pages 719-729"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipidomic Profiling of a Preclinical Model of Streptozotocin-Induced Diabetic Cardiomyopathy Reveals Potential Plasma Biomarkers","authors":"Bianca C. Bernardo PhD ,&nbsp;Alexandra N. Faulkner BSc ,&nbsp;Tingting Wang PhD ,&nbsp;Kevin Huynh PhD ,&nbsp;Peter J. Meikle PhD ,&nbsp;Kate L. Weeks PhD ,&nbsp;Yow Keat Tham PhD","doi":"10.1016/j.hlc.2024.11.036","DOIUrl":"10.1016/j.hlc.2024.11.036","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 7","pages":"Pages 739-742"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The DanGer Shock Trial: Implications for Cardiogenic Shock Management in Australia","authors":"Pankaj Jain MBBS, PhD ,&nbsp;Paul Forrest MBChB ,&nbsp;Brian Plunkett MBChB ,&nbsp;Christopher Hayward MBBS, MD ,&nbsp;Mark Dennis MBBS, PhD","doi":"10.1016/j.hlc.2025.03.019","DOIUrl":"10.1016/j.hlc.2025.03.019","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 7","pages":"Pages 670-673"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to Rethink our Approach to Guidelines? International Cascade Guidelines for Heart Failure","authors":"John J. Atherton MBBS, PhD ,&nbsp;Andrew P. Sindone BMed, MD ,&nbsp;Andrew J.S. Coats MA, MBBChir, DM, DSc","doi":"10.1016/j.hlc.2025.05.093","DOIUrl":"10.1016/j.hlc.2025.05.093","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 7","pages":"Pages 651-653"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}